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Abstract 
Finasteride has been used extensively until now as a relative efficient therapeutic option for male androgenic alopecia and 
benign prostatic hyperplasia. Unfortunately, over time several concerns appeared regarding the frequency and magnitude of 
adverse effects, which in some cases have been even irreversible. Herein we review the recent literature on this topic, trying 
to clarify the current safety profile of Finasteride for these two therapeutic indications. We concluded that Finasteride could 
be retained as a therapeutic approach for male androgenic alopecia, based on two important reasons. First, a synergistic 
action between a partial inhibitor of 5α-reductase (Finasteride) and another compound (like Minoxidil) are preferable to a 
complete suppression of 5α-reductase (see Dutasteride), in order to preserve the important physiological roles of 
dihydrotestosterone. Second, Finasteride side effects can currently be addressed in part prior to the onset of the therapy, by 
using information about the patient such as hand preference and sexual orientation to predict the risk of adverse effects. 
 
Rezumat 
Finasterida a fost utilizată pe scară largă până acum pentru alopecia androgenică masculină și hiperplazia benignă de prostată, 
fiind o opțiune terapeutică relativ eficientă. Cu timpul însă au apărut tot mai multe preocupări legate de frecvența și 
amploarea efectelor adverse, care au fost chiar ireversibile în unele cazuri. Acest articol prezintă o revizuire a literaturii de 
specialitate pe această temă cu scopul de a clarifica profilul de siguranță al Finasteridei pentru cele două recomandări 
terapeutice. Concluzia este că Finasterida ar putea fi menținută ca și soluție terapeutică pentru alopecia androgenică 
masculină, din două motive importante. Primul aspect vizează menținerea rolurilor fiziologice specifice 
dihidrotestosteronului, pentru care ar fi de preferat o acțiune sinergică între un inhibitor parțial de 5α-reductază (Finasterida) 
și un alt compus precum Minoxidil, față de o suprimare completă a 5α-reductazei (specifică Dutasteridei). Cel de-al doilea 
element este legat de reacțiile adverse ale Finasteridei care pot fi avute în vedere chiar și înainte de începerea tratamentului, 
caracteristici individuale precum mâna dominantă și orientarea sexuală ale pacientului fiind corelate cu riscul și frecvența 
efectelor adverse. 
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Introduction 
Male androgenic alopecia and benign prostatic hyper-
plasia are relatively common conditions encountered 
in elderly male subjects. Their occurrence and 
progression are partly supported by the androgenic 
action of male sex hormone, dihydrotestosterone 
(DHTT). Consequently, several drugs like Finasteride 
and Dutasteride that interfere with DHTT synthesis 
have been evaluated and implemented as therapeutic 
solutions to ameliorate these two conditions [3, 17]. 
The pharmacologic action of Finasteride (especially 
its efficacy in decreasing levels of DHTT) has been 
demonstrated through laboratory tests assessing 
cerebrospinal fluid and plasma in populations of 
men receiving Finasteride [4, 15]. However, recent 
studies suggest that Finasteride side effects seem to 
be encountered only in a subset of men [7, 16], with 
the aggregation of Finasteride adverse effects 
apparently related to lateralization processes of the 
brain [24, 25]. As a consequence, Finasteride use and 
monitoring should take into consideration not only the 
general pharmacological properties (pharmacokinetics 
and pharmacodynamics) of the drug, but also specific 
patient characteristics that are linked to lateralization 
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process of the brain such as hand preference and 
sexual orientation. 
Indeed, recent data suggest that hand preference 
(left or right) and sexual orientation may be associated 
with the occurrence and severity of Finasteride adverse 
effects [24, 25]. In such predisposed men, Finasteride 
administration is relatively difficult to manage due to 
the variety and magnitude of adverse effects, (including 
but not limited to severe depression and sexual 
dysfunctions associated with suicidal thoughts) as 
well as their indefinite and irreversible persistence even 
after cessation of pharmacological action (commonly 
referred to as post-finasteride syndrome) [5, 14, 15, 36]. 
This paper presents the pharmacological profile of 
Finasteride and the corresponding neurobiological 
substrate able to explain the occurrence of various 
Finasteride side effects among different populations 
of patients. Such information could help provide the 
basis for reconsidering the therapeutic safety profile 
of Finasteride in the treatment of male androgenic 
alopecia and benign prostatic hyperplasia. 
 
Pharmacological profile of Finasteride 
Finasteride is a partial inhibitor (only type II) of 5α-
reductase enzyme, which converts intracellular 
testosterone to dihydrotestosterone. This enzyme is 
encountered in the sebaceous glands and liver (type I 
isoenzyme), and also in prostate, seminal vesicles, and 
hair follicles (type II isoenzyme). After Finasteride 
administration, the serum DHTT concentration 
decreases up to 70%, indicating that the type II 
isoenzyme generates about two-thirds of the circulating 
DHTT, whereas the type I isoenzyme is responsible 
for only one-third of the circulating DHTT [31]. 
In men with male androgenetic alopecia there are 
high amounts of DHTT and also miniaturized hair 
follicles in the balding scalp, compared with the 
hairy scalp. By reducing DHTT, Finasteride interrupts 
an important factor implied in the occurrence of 
androgenetic alopecia, which is considered a genetically 
predisposed condition. In patients with benign 
prostatic hyperplasia, the prostate volume decreases 
during Finasteride administration by approximately 
20%, returning often to the baseline value about three 
months after discontinuation of therapy [22, 35]. 
Finasteride absorption is not affected by food, 
presenting a bioavailability around 65%. The maximum 
plasmatic concentration is reached about 1 to 2 
hours after administration, ranging between 4.9 - 
13.7 ng/mL for 1 mg/day, and between 27 - 49 ng/mL 
for 5 mg/day. After successive doses, there is a 
slow accumulation phase for Finasteride, with 90% 
of the circulating drug bound to plasma proteins. 
Finasteride crosses the blood-brain barrier, a property 
that explains many Finasteride side effects such as 
mental and sexual impairments. It is extensively 
metabolized by the liver, especially through cytochrome 
P450 3A4 enzyme subfamily. The corresponding 
metabolites possess no more than 20% inhibitory 
activity for 5α-reductase comparable to Finasteride 
action. Oral administration of Finasteride leads to 
its excretion in urine as metabolites (about 39%) 
and through faeces (57%, in part unmetabolized). 
The mean terminal half-life of finasteride in men 
between 45 - 60 years is approximately 6 hours, 
though longer in men over 70 years (about 8 hours) 
[44]. 
Finasteride administration produces a relatively rapid 
decrease of serum DHTT concentration within 6 - 8 
hours, which persists over the 24-hour dosing interval, 
or longer for repeated administration. Daily dosing 
of finasteride has been shown to suppress serum 
DHTT concentration by approximately 65% for a 1 mg 
tablet, and 70% for 5 mg. Compared to baseline, the 
mean circulating levels of testosterone and estradiol 
increase up to 15%, remaining however for most 
subjects within the physiologic range. In a similar 
manner, the luteinizing hormone (LH) and follicle 
stimulating hormone (FSH) increase during Finasteride 
administration by about 10%, without exceeding 
the physiological level. Thus the hypothalamic-
pituitary-testicular axis is not affected. No effect 
has been reported on thyroid-stimulating hormone, 
cortisol, prolactin, plasma lipid profile or bone 
mineral density [1, 36]. 
Finasteride side effects are the consequence of its 
direct actions on the brain and peripheral organs 
(nausea, vomiting, allergies, etc.), and due to indirect 
actions of the drug through dihydrotestosterone and 
possible GABA receptors [36]. The most frequent 
adverse effects are represented by mental (depression, 
suicidal ideations, anhedonia, lack of mental 
concentration, etc.) and sexual (impotence, erectile 
dysfunction, decreased libido, ejaculation disorders) 
impairments. Other adverse effects are also possible: 
insomnia, gynecomastia, chronic fatigue, elevated 
body mass index, pruritus, rash, urticaria, angioedema, 
gingival hypertrophy, etc. (Table I) [21, 30]. 
Finasteride also seems to change tolerance to ethanol 
in many individuals, with former users of finasteride 
reporting a decreased tolerance to alcohol [14, 46]. 
Finally, studies have noted several concerns related 
to association or even possible causal relationship 
between finasteride administration and high-grade 
prostate cancers, or male breast cancer [19, 39]. 
 
Therapeutic window and therapeutic opportunity 
of Finasteride 
General data regarding Finasteride administration  
Finasteride was introduced primarily as a therapeutic 
solution for benign prostatic hyperplasia (5 mg 
daily), ameliorating specific symptoms such as night 
time urination, decreased flow, prolonged initiation, 
etc. [40].  
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Table I 
Finasteride adverse effects (administration: four months or more) [21, 36] 
Adverse effects Finasteride, 1 mg (%) Placebo (%) Finasteride, 5 mg (%) Placebo (%) 
Depression 11.76 3.92 7.44 3.19 
Anhedonia 21.56 4.90 19.14 5.31 
Lack of mental concentration 17.64 8.82 20.21 11.07 
Suicidal ideations 5.88 0 3.19 1.06 
Impotence  7.84 1.96 9.57 2.12 
Decreased Libido  16.66 2.94 22.34 5.31 
Ejaculation Disorder  6.86 0.0 8.51 1.06 
Gynecomastia 4.90 0 6.38 1.06 
Rash  2.94 0.98 4.25 1.06 
Pruritus 3.92 0.98 3.19 2.12 
Gingival hypertrophy 1.96 0 1.06 0 
 
After five years, Finasteride was also approved and 
introduced for the therapeutic management of male 
androgenic alopecia (at a dose of 1 mg/day) due to 
its effect of improving hair stretch by up to 20 - 
30% [8]. 
These therapeutic effects are usually obtained six 
months or more after finasteride administration, 
being maintained only so long as the drug is 
administered [35]. Such prolonged administration 
increases the therapeutic benefits of the drug, but 
unfortunately also the frequency and magnitude of 
adverse effects [36]. Some adverse effects were 
noted from the drug’s outset during preclinical 
studies, while others were noted later (during the 
post-market experience) [46]. 
A comprehensive and historically accurate approach 
has revealed two distinct findings. First, Finasteride 
side effects are encountered not only during 
Finasteride administration but also after discontinuation, 
known as the post-Finasteride syndrome [36]. 
Second, it has been observed that some men 
tolerate Finasteride quite well, with only a sub-
group of patients developing notable and eventually 
irreversible adverse effects (severe depression, sexual 
dysfunctions, suicidal thoughts, etc.), requiring 
drug discontinuation [7, 16]. For these two reasons 
several authors have suggested that Finasteride 
administration should be re-evaluated [46]. 
Therapeutic window and therapeutic opportunity of 
Finasteride 
The `therapeutic window` typically refers to the 
pharmacological evaluation of a drug (in terms of 
optimal biological dose/ time) so as to produce 
optimal efficacy while remaining in the range of 
acceptable toxicity/ adverse effects. When the 
therapeutic effect is insignificant and/ or toxicity 
(adverse effects) becomes unacceptable, the value 
of the drug becomes questionable [32]. In the case of 
Finasteride, preliminary data on patient complaints 
during the post-market period suggested that adverse 
effects were occurring more frequently than initially 
assumed, with greater severity and persistence, 
sometimes indefinitely even after the treatment was 
terminated [5, 14]. For these reasons, the therapeutic 
window of Finasteride appeared to warrant re-
evaluation (a relatively difficult process through the 
classical tools) [46]. 
The “therapeutic opportunity” is generally applied 
to preliminary investigations designed to evaluate 
the opportunity of a drug for certain diseases/ 
patients [33]. In the case of Finasteride, after its 
initial use, a second perspective evolved based on 
observations that severe and persistent adverse 
effects were encountered only in select patients; 
other patients reported no complaints with respect 
to drug administration [7, 16]. As a consequence, the 
second perspective maintained that the therapeutic 
window was relatively safe for some patients 
(reporting no adverse effects), and further, that the 
therapeutic opportunity was actually the issue of 
concern, and it therefore should be reconsidered for 
the subgroup of patients susceptible to developing 
severe adverse effects [24, 25]. But this process 
implies the formulation of relevant criteria that 
differentiate this highly susceptible subgroup of 
patients from those less or non-susceptible. So far, 
two potential criteria have been identified - hand 
preference and sexual orientation - that can help 
predict the severity and type of adverse effects in 
men under treatment [24, 25]. To understand why 
some men respond with severe adverse effects 
while others do not present adverse effects requires 
an understanding of the neurobiological system 
supporting this dual response. 
The neurobiological substrate responsible by 
distribution of Finasteride side effects 
Anatomically, the human brain is divided by the 
median plane into two different (left and right) 
hemibrains. Each cerebral event is processed usually 
in only one hemibrain (identified as the dominant 
hemibrain), the opposite hemibrain supporting only 
the neurological connection between dominant 
hemibrain and peripheral receptors/effectors [29]. 
This asymmetric functioning of the brain is known 
as lateralization, being possible from a physiologic 
perspective through intervention of different neuro-
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modulators that channel environmental information 
towards either the left or the right hemibrain [18, 
37]. Without such preferential channelling, the left 
and right hemibrains could receive, process, and 
elaborate two distinct responses (competitive or, 
even more problematic, contradictory) to the same 
external stimulus/information, an eventuality that 
would be not only inefficient, but also counter-
productive [29]. 
With respect to sexuality, oestrogens modulate 
environmental inputs especially toward the left 
hemibrain. As a consequence, women exposed 
prenatally to the synthetic oestrogen diethyl-
stilbestrol are more likely to be left handed for 
writing during development [41]. By the same 
rationale, administration of antioestrogens such as 
Tamoxifen induces sexual impairments especially 
in left handed men [2, 26]. At the other end of the 
spectrum, androgens channel the same environmental 
information/inputs toward the contralateral/right 
hemibrain [9]. In this respect, administration of 
Finasteride or Bicalutamide induces sexual dysfunction 
predominantly in right handed men [23, 27]. During 
puberty, cortical maturation entails especially the left 
hemibrain in human males, while in human females 
this maturation involves predominantly the right 
hemibrain [28, 36]. 
Regarding the lateralized action of pheromones, in 
heterosexual men (sensitive to female pheromones) 
the process of sexual activation involves especially 
the right hemibrain (right hippocampus, right para-
hippocampal gyrus, etc.). In contrast, in homosexual 
men (sensitive to male pheromones) the process of 
sexual activation implies predominantly the left 
hemibrain (the left angular gyrus, left caudate 
nucleus, etc.) [11]. In support of this lateralized 
process, heterosexual men and homosexual women 
(lesbians) present a rightward volumetric cerebral 
asymmetry (their connections being more widespread 
from the right amygdala), while homosexual men 
and heterosexual women display more widespread 
connections from the left amygdala [38]. In 
addition, empirical evidence indicates that homosexual 
and heterosexual men are different regarding the 
sizes/volume of hypothalamic nuclei [20]. 
Finasteride side effects according to lateralized 
process of the brain 
Returning to Finasteride administration in men, 
sexual side effects are directly linked to decreasing 
levels of DHTT. But the action of DHTT is strongly 
related (through the right hemibrain) to a right 
handed preference and female sexual pheromones/ 
heterosexual orientation. As a consequence, it is not 
surprising that sexual side effects of Finasteride are 
correlated with hand preference and sexual orientation. 
In other words, hand preference and sexual 
orientation could be used (prior to the treatment) as 
possible eligibility criteria for selecting patients 
having a low risk for developing sexual side effects 
to 5α-reductase inhibitors like Finasteride. 
Similar to sexual dysfunctions, psychological/cognitive 
impairments resulting from Finasteride administration 
are also directly related to lateralization processes in 
the brain. Specifically, existing interrelations between 
cognition and sexuality [29] can be highlighted 
through several poignant examples. For example, 
depression is closely related to estrogenic action, 
being more frequently encountered in women than 
men [34]. In addition, the incidence of depression 
(associated with an inter-hemispheric imbalance) is 
higher in left handed persons who present a 
hyperactive right-hemisphere, due perhaps to an 
inadequate or, alternatively, excessive activation of the 
left hemibrain under estrogenic neuromodulation [6]. 
We limited the discussion above to the depressive 
and sexual side effects of Finasteride, ones that are 
sometimes severe and among those encountered more 
frequently (being interrelated through lateralization 
process of the brain). These processes may set up a 
vicious neuro-endocrine cycle, with each (depressive 
and sexual side effects) maintaining or intensifying 
the other, and sometimes can persist indefinitely 
after Finasteride cessation [36]. Beyond these 
effects, Finasteride can also induce other adverse 
effects that are related either to the direct presence 
and action of the drug (pruritus, rash, urticaria, 
gingival hypertrophy, etc.), or to other mechanisms 
that are not hormonally mediated. As an example, 
Finasteride administration may affect tolerance to 
ethanol (through GABAA receptors), with many 
former users of finasteride reporting decreased 
tolerance and disturbing effects from alcohol 
consumption (leading some men to stop drinking 
entirely) [13, 46]. Other studies show that Finasteride 
blocks the effects of dopamine receptors in the 
nucleus accumbens, having thus a therapeutic 
potential for certain neuropsychiatric disorders like 
schizophrenia [42]. 
Summarizing, the therapeutic approach of male 
androgenic alopecia and benign prostatic hyper-
plasia with Finasteride presented four successive 
phases. The initial period was represented by approval 
and introduction of the drug into clinical practice. 
The enthusiasm generated and sustained by initial 
therapeutic results was followed by a second, early 
post-market period of patient complaints of increased, 
more severe, and even irreversible adverse effects 
that continued even after Finasteride cessation [46]. 
The third phase involved identifying of alternative or 
personalized therapeutic solutions for male 
androgenic alopecia and benign prostatic hyperplasia, 
with fewer side effects and eventually superior 
therapeutic results [3, 35]. Thus, Dutasteride was 
often used as a replacement for Finasteride in the 
therapeutic approach of benign prostatic hyperplasia 
[3], a trend that was extended to androgenic 
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alopecia as well [8, 45]. Finally, the last phase - the 
one that is currently emerging - suggests that 
Finasteride should be reconsidered as a therapeutic 
approach of androgenic alopecia [36]. 
 
Conclusions 
In conclusion, Finasteride could be further retained as 
a therapeutic approach of male androgenic alopecia, 
based on three important reasons. 
First, male androgenic alopecia and benign prostatic 
hyperplasia are only partly supported by DHTT 
(other factors being also involved) [43], and DHTT 
has its own important physiological roles within the 
body [12]. Consequently, it makes more sense 
physiologically to suppress DHTT synthesis only 
partially (as Finasteride does) rather than almost 
completely (as Dutasteride does). However, to 
increase the therapeutic effects of Finasteride, we 
suggest that the synergistic actions of drug 
combinations (Finasteride plus Minoxidil, for 
example, for androgenic alopecia) [10] could 
provide a more suitable resolution than maximizing 
a single drug effect (e.g., severe suppression of 
DHTT by replacing Finasteride with Dutasteride). 
Second, even if Finasteride adverse effects are 
more frequent or severe than initially assumed, 
recent evidence suggests that such adverse effects 
are (at least in part) predictable, meaning that 
screening of patients on a priori criteria (according 
to current and forthcoming criteria) could lead to a 
better compliance by patients. 
Finally, adverse effects induced by Finasteride are 
still being documented and studied, a difficult task 
given that neither mental or sexual functions (often 
affected in tandem by Finasteride) on one hand, nor 
postfinasteride syndrome on the other hand, have 
been completely described. Understanding their 
link will require additional investigations regarding 
symptomatology and the optimal therapeutic approach 
to address the adverse effects [5]. 
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